Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tyler Y. Kang"'
Autor:
Wei Ye, Tyler Y. Kang, Peter W. Nichols, Derek Raghavan, Eila C. Skinner, Greg Valin, Susan Groshen
Publikováno v:
BJU International. 99:1024-1027
To use a clinical model of androgen-deprivation therapy (ADT) followed by radical prostatectomy (RP) to test the hypothesis that prostatic intraepithelial neoplasia (PIN, a premalignant lesion of the prostate causally linked to prostate cancer) is he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::795b1ad5ae1f300b4e2de7859b20cce1
https://doi.org/10.1111/j.1464-410x.2006.06738.x
https://doi.org/10.1111/j.1464-410x.2006.06738.x
Autor:
Lisa Rybicki, Robert M. Dean, Brad Pohlman, Anjali S. Advani, Stephen D. Smith, John Sweetenham, Ronald Sobecks, Matt Kalaycio, Brian J. Bolwell, Snehal G. Thakkar, Tyler Y. Kang
Publikováno v:
Bone marrow transplantation. 46(2)
The standard approach for relapsed diffuse large B-cell lymphoma (DLBCL) involves auto-SCT. However, studies that established this approach were conducted before the inclusion of rituximab (R) with first-line therapy became routine. Whether DLBCL pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa0ac7cc32d43be5b7928f5d57fe33a9
https://pubmed.ncbi.nlm.nih.gov/20479706
https://pubmed.ncbi.nlm.nih.gov/20479706
Autor:
Snehal G. Thakkar, Stacey Brown, Tyler Y. Kang, Matt Kalaycio, Ronald Sobecks, John Sweetenham, Anjali S. Advani, Robert M. Dean, Brian J. Bolwell, Brad Pohlman, Mikkael A. Sekeres, Lisa Rybicki
Publikováno v:
Bone marrow transplantation. 40(10)
Autologous stem-cell transplantation (ASCT) has been used in follicular lymphoma (FL) to achieve durable responses in first remission or in the relapsed or refractory settings. Addition of rituximab to chemotherapy for FL has been shown to improve su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e4d5eb0d6cd45f88904b8db4129edcb
https://pubmed.ncbi.nlm.nih.gov/17873917
https://pubmed.ncbi.nlm.nih.gov/17873917
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
Publikováno v:
Journal of neuro-oncology. 89(1)
Recurrent high-grade gliomas are resistant to chemotherapy and have poor prognosis. The combination of irinotecan and bevacizumab has been reported to be an active regimen in the treatment of this disease. Herein we report our experience with this re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d0ebb851f800035c0a926f9cd0be88
https://pubmed.ncbi.nlm.nih.gov/18438609
https://pubmed.ncbi.nlm.nih.gov/18438609
Publikováno v:
Journal of Clinical Oncology. 25:2077-2077
2077 Background: High-grade gliomas are generally resistant to modern chemotherapy. In the case of glioblastoma multiforme, median overall survival has been less than 12 months and progression free survival of less than 4 months. For patients with re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ca81400df1cac2759b32da3e2c926c5
https://doi.org/10.1200/jco.2007.25.18_suppl.2077
https://doi.org/10.1200/jco.2007.25.18_suppl.2077
Publikováno v:
Journal of Clinical Oncology. 24:5328-5328
A 60-year-old woman who presented initially with splenomegaly and petechiae underwent evaluation with a bone marrow biopsy, which revealed a diagnosis of chronic idiopathic myelofibrosis (with extramedullary hematopoiesis). She was initiated on thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bf64d58502eccc3a7eb4e0ffe493269
https://doi.org/10.1200/jco.2006.06.7371
https://doi.org/10.1200/jco.2006.06.7371
Autor:
Lisa Rybicki, Brian J. Bolwell, Snehal G. Thakkar, Stacey Brown, John Sweetenham, Tyler Y. Kang, Brad Pohlman, Anjali S. Advani, Robert M. Dean, Matt Kalaycio, Mikkael A. Sekeres, Ronald Sobecks
Publikováno v:
Blood. 108:3069-3069
ASCT has been used in FL to achieve durable remissions either as consolidation therapy in first remission or as salvage therapy in the relapsed or refractory setting. The recent addition of R to chemotherapy regimens for FL has been shown to improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf304c2dbf80aabc0feed6cb4a225887
https://doi.org/10.1182/blood.v108.11.3069.3069
https://doi.org/10.1182/blood.v108.11.3069.3069